Sponsored Links
| New Data Show Renal Impairment Is Strong Predictor Of Early Death In Patients With PNH |
 |
 |
 |
| Medical News - Hematology | |||
|
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes... Read more: Blood / Hematology News From Medical News Today
|